EUVIMEDEUVIMED entdecken
Multizentrische Studie

[ 18 F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

David L Chan, Aimee Hayes, Ioannis Karfis, Alice Conner, Magdalena Mileva, Elizabeth Bernard, Shaunak Navalkissoor, Gopinath Gnanasekaran, Stephen J Clarke, Paul J Roach, Patrick Flamen, Martyn E Caplin und 3 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.269031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von David L Chan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; david.chan@sydney.edu.au. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Tumor Burden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Neuroendocrine TumorsPositron Emission Tomography Computed TomographyTumor BurdenPancreatic NeoplasmsIntestinal NeoplasmsStomach NeoplasmsHumansMaleFemaleMiddle AgedPrognosisRetrospective StudiesAgedAdultAged, 80 and over

Stichwörter der Autor:innen

PET imaging[18F]FDGmetabolic tumor volumeprognostic biomarker

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Medical Oncology Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; david.chan@sydney.edu.au.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
  • Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
  • Nuclear Medicine Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; and.
  • Nuclear Medicine Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.

Zitieren

APA

Chan, D. L., Hayes, A., Karfis, I., Conner, A., Mileva, M., Bernard, E., Navalkissoor, S., Gnanasekaran, G., Clarke, S. J., Roach, P. J., Flamen, P., Caplin, M. E., Pavlakis, N., Toumpanakis, C., & Bailey, D. L. (2025). [ 18 F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269031

Vancouver

Chan DL, Hayes A, Karfis I, Conner A, Mileva M, Bernard E, et al. [ 18 F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269031

BibTeX
@article{Chan2025,
  author = {Chan, David L and Hayes, Aimee and Karfis, Ioannis and Conner, Alice and Mileva, Magdalena and Bernard, Elizabeth and Navalkissoor, Shaunak and Gnanasekaran, Gopinath and Clarke, Stephen J and Roach, Paul J and Flamen, Patrick and Caplin, Martyn E and Pavlakis, Nick and Toumpanakis, Christos and Bailey, Dale L},
  title = {[ 18 F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.269031}
}
Kostenlos starten →